Assessment of the WATCHMAN Device in Patients Unsuitable for Oral Anticoagulation
Principal Investigator (?)
The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.
Boston Scientific Corporation
Available at the following location(s)